AI Article Synopsis
- The study focuses on a new cancer therapy that uses near-infrared (IR) light to activate a platinum-based compound, IR797-Platin, which enhances its ability to damage cancer cells.
- When exposed to near-IR light, IR797-Platin shows a significant increase in its effectiveness, with cytotoxicity improved by 30-60 times across various cancer cell lines.
- This is the first instance of a treatment that combines the harmful effects of cisplatin (a common chemotherapy drug) and singlet oxygen, highlighting its potential for targeted cancer therapy through light activation.
Article Abstract
Controlled generation of cytotoxic agents with near-IR light is a current focus of photoactivated cancer therapy, including that involving cytotoxic platinum species. A heptamethine cyanine scaffolded Pt complex, IR797-Platin exhibits unprecedented Pt-O bond scission and enhancement in DNA platination in near-IR light. This complex also displayed significant singlet oxygen quantum yield thereby qualifying as a near-IR photodynamic therapeutic agent. The complex showed 30-60 fold enhancement of cytotoxicity in near-IR light in various cancer cell lines. The cellular imaging properties were also leveraged to observe its significant co-localization in cytoplasmic organelles. This is the first demonstration of a near-IR light-initiated therapy involving the cytotoxic effects of both active cisplatin and singlet oxygen.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548462 | PMC |
| http://dx.doi.org/10.1002/anie.201806911 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!